source
- Vera Therapeutics' Trutakna shows kidney function stabilization and lower death risk in Phase 3 IgAN trialVera Therapeutics reported that its drug Trutakna met its primary goals in a two‑year Phase 3 study of patients with IgA nephropathy. The therapy stabilized kidney function and lowered the risk of…
- FDA approves Moderna’s mRNA flu vaccine as company reports positive Phase 3 cancer vaccine resultsThe FDA has granted approval to Moderna’s mRNA‑based flu vaccine, marking a notable rebound for the technology after the Trump administration cut $500 million in funding for mRNA programs a year ea…